AZ in pricing deal with US
AstraZeneca Plc has become the second global pharmaceutical company to sign an agreement with the Trump Administration to lower the prices of its medicines sold in the US. In parallel it will increase its manufacturing presence in the country and upgrade its share listing. Pfizer Inc signed a similar agreement with the government on 30 September. The deals are applications of the World Trade Organization’s most-favoured nation principle (MFN) under which favourable terms of trade, like lower tariffs, extended to one country are granted to other WHO members as well.
